600420 国药现代
交易中 08-21 13:16:36
资讯
新帖
简况
国药现代：公司将定期汇总包括上证互动易在内的各个渠道的投资者建议，并报告给董事会及公司相关领导
证券之星 · 08-20 17:21
国药现代：公司将定期汇总包括上证互动易在内的各个渠道的投资者建议，并报告给董事会及公司相关领导
国药现代：聚焦核心优势领域，综合研判积极推进科研工作
证券之星 · 08-20 17:21
国药现代：聚焦核心优势领域，综合研判积极推进科研工作
股市必读：国药现代新发布《关于全资子公司药品通过仿制药一致性评价的公告》
证券之星 · 08-20 02:06
股市必读：国药现代新发布《关于全资子公司药品通过仿制药一致性评价的公告》
国药现代最新公告：拟4.06亿元收购国瑞药业51%股权
证券之星 · 08-19 18:25
国药现代最新公告：拟4.06亿元收购国瑞药业51%股权
国药现代（600420）披露全资子公司药品通过仿制药一致性评价公告，8月18日股价下跌0.57%
证券之星 · 08-18 22:30
国药现代（600420）披露全资子公司药品通过仿制药一致性评价公告，8月18日股价下跌0.57%
国药现代最新公告：子公司维生素B12注射液通过一致性评价
证券之星 · 08-18 17:40
国药现代最新公告：子公司维生素B12注射液通过一致性评价
股市必读：国药现代新发布《关于全资子公司药品通过仿制药一致性评价的公告》
证券之星 · 08-17
股市必读：国药现代新发布《关于全资子公司药品通过仿制药一致性评价的公告》
国药现代（600420）披露全资子公司药品通过仿制药一致性评价公告，8月14日股价上涨0.11%
证券之星 · 08-14
国药现代（600420）披露全资子公司药品通过仿制药一致性评价公告，8月14日股价上涨0.11%
国药现代最新公告：子公司阿莫西林克拉维酸钾干混悬剂通过仿制药一致性评价
证券之星 · 08-14
国药现代最新公告：子公司阿莫西林克拉维酸钾干混悬剂通过仿制药一致性评价
8月13日国药现代发生1笔大宗交易 成交金额1.37亿元
证券之星 · 08-13
8月13日国药现代发生1笔大宗交易 成交金额1.37亿元
股市必读：国药现代新发布《2026年第一次临时股东会会议资料》
证券之星 · 08-12
股市必读：国药现代新发布《2026年第一次临时股东会会议资料》
国药现代（600420）披露2026年第一次临时股东会会议资料，8月10日股价上涨0.57%
证券之星 · 08-10
国药现代（600420）披露2026年第一次临时股东会会议资料，8月10日股价上涨0.57%
股市必读：国药现代新发布《关于全资子公司获得药品注册证书的公告》
证券之星 · 08-10
股市必读：国药现代新发布《关于全资子公司获得药品注册证书的公告》
每周股票复盘：国药现代（600420）拟中选五款集采药品
证券之星 · 08-09
每周股票复盘：国药现代（600420）拟中选五款集采药品
国药现代（600420）披露全资子公司获得药品注册证书，8月6日股价下跌1.27%
证券之星 · 08-06
国药现代（600420）披露全资子公司获得药品注册证书，8月6日股价下跌1.27%
国药现代(600420.SH)子公司获比索洛尔氨氯地平片药品注册证书
智通财经 · 08-06
国药现代(600420.SH)子公司获比索洛尔氨氯地平片药品注册证书
国药现代：坚持“内生+外延”双轮驱动是公司明确的发展路径
证券之星 · 08-06
国药现代：坚持“内生+外延”双轮驱动是公司明确的发展路径
国药现代：新聘总裁及董事将助力公司高质量发展
证券之星 · 08-06
国药现代：新聘总裁及董事将助力公司高质量发展
国药现代：沙库巴曲缬沙坦钠片和布瑞哌唑片处于CDE审评审批阶段
证券之星 · 08-06
国药现代：沙库巴曲缬沙坦钠片和布瑞哌唑片处于CDE审评审批阶段
国药现代：不存在国有资产流失的情况
证券之星 · 08-06
国药现代：不存在国有资产流失的情况
加载更多
公司概况
公司名称：
上海现代制药股份有限公司
所属行业：
医药制造业
上市日期：
2004-06-16
主营业务：
上海现代制药股份有限公司的主营业务是医药产品研发、生产与销售。公司的主要产品是6-APA、7-ACA、D-7ACA、青霉素工业钾盐、头孢曲松钠粗盐、氨苄西林酸。在制剂产品方面，根据米内网数据库显示，公司头孢呋辛酯片、注射用甲泼尼龙琥珀酸钠国内市场占有率稳居行业第一；头孢克肟颗粒市场份额进一步提升，展现出良好的增长态势；硝苯地平控释片、盐酸米那普仑片市场占有率稳居仿制药企业第一。
发行价格：
8.08
{"stockData":{"symbol":"600420","market":"SH","secType":"STK","nameCN":"国药现代","latestPrice":8.44,"timestamp":1787289396000,"preClose":8.8,"halted":0,"volume":14352809,"delay":0,"changeRate":-0.0409,"floatShares":1341000000,"shares":1341000000,"eps":0.5358,"marketStatus":"交易中","change":-0.36,"latestTime":"08-21 13:16:36","open":8.8,"high":8.8,"low":8.4,"amount":122000000,"amplitude":0.0455,"askPrice":8.45,"askSize":495,"bidPrice":8.44,"bidSize":271,"shortable":0,"etf":0,"ttmEps":0.5358,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1787295600000},"marketStatusCode":2,"adr":0,"adjPreClose":8.8,"symbolType":"stock","openAndCloseTimeList":[[1787275800000,1787283000000],[1787288400000,1787295600000]],"highLimit":9.68,"lowLimit":7.92,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1341172692,"isCdr":false,"pbRate":0.85,"roa":"--","peRate":15.752146,"roe":"1.0%","epsLYR":0.7021,"committee":0.76482,"marketValue":11319000000,"turnoverRate":0.0107,"status":1,"floatMarketCap":11319000000},"requestUrl":"/m/hq/s/600420/","defaultTab":"news","newsList":[{"id":"2660400684","title":"国药现代：公司将定期汇总包括上证互动易在内的各个渠道的投资者建议，并报告给董事会及公司相关领导","url":"https://stock-news.laohu8.com/highlight/detail?id=2660400684","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660400684?lang=zh_cn&edition=full","pubTime":"2026-08-20 17:21","pubTimestamp":1787217678,"startTime":"0","endTime":"0","summary":"证券之星消息，国药现代08月20日在投资者关系平台上答复投资者关心的问题。公司将定期汇总包括上证互动易在内的各个渠道的投资者建议，并报告给董事会及公司相关领导。如您有具体的建议，欢迎提出，我们将转送有关责任部门研究。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000030540.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0132","BK0010","BK0020","BK0082","600420"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660400686","title":"国药现代：聚焦核心优势领域，综合研判积极推进科研工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2660400686","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660400686?lang=zh_cn&edition=full","pubTime":"2026-08-20 17:21","pubTimestamp":1787217674,"startTime":"0","endTime":"0","summary":"证券之星消息，国药现代08月20日在投资者关系平台上答复投资者关心的问题。投资者提问：80%以上的央企都在立项自己行业科研创新攻坚项目，目的要突破国外技术封锁，完全自主可控！公司将本着为股东负责的原则，围绕战略规划，聚焦核心优势领域，综合研判积极推进科研工作，持续优化产品管线布局，推动公司高质量研发。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000030536.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0010","BK0239","600420","BK0020","BK0082","BK0132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660342703","title":"股市必读：国药现代新发布《关于全资子公司药品通过仿制药一致性评价的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2660342703","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660342703?lang=zh_cn&edition=full","pubTime":"2026-08-20 02:06","pubTimestamp":1787162776,"startTime":"0","endTime":"0","summary":"公司公告汇总：董事会选举冯军为董事长，并审议通过以40,636.34万元收购国药集团国瑞药业51%股权的关联交易议案。公司公告汇总：全资子公司维生素B12注射液新增1ml:1mg规格并获批通过仿制药一致性评价。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000002042.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600420","BK0082","BK0020","BK0132","BK0239","BK0010"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660440224","title":"国药现代最新公告：拟4.06亿元收购国瑞药业51%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2660440224","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660440224?lang=zh_cn&edition=full","pubTime":"2026-08-19 18:25","pubTimestamp":1787135134,"startTime":"0","endTime":"0","summary":"国药现代(600420.SH)公告称，公司以现金4.06亿元收购国药集团国瑞药业51%股权，交易对方为国药集团、国药控股及国药股份。收购完成后，国瑞药业将成为公司控股子公司，此举旨在消除同业竞争，丰富神经系统、抗感染等领域产品管线。本次交易构成关联交易，不构成重大资产重组，无需提交股东会审议。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081900032485.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","BK0010","BK0239","BK0020","600420","BK0082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660911493","title":"国药现代（600420）披露全资子公司药品通过仿制药一致性评价公告，8月18日股价下跌0.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660911493","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660911493?lang=zh_cn&edition=full","pubTime":"2026-08-18 22:30","pubTimestamp":1787063434,"startTime":"0","endTime":"0","summary":"截至2026年8月18日收盘，国药现代报收于8.65元，较前一交易日下跌0.57%，最新总市值为116.01亿元。近日，上海现代制药股份有限公司全资子公司国药集团容生制药有限公司收到国家药品监督管理局核准签发的《药品补充申请批准通知书》，批准维生素B12注射液增加1ml:1mg规格，并通过仿制药质量和疗效一致性评价。截至目前，国药容生该项目累计研发投入约316.32万元。本次通过一致性评价有利于产品未来市场拓展和销售，但对当期经营业绩无重大影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081800042664.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","BK0082","600420","BK0239","BK0020","BK0010"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660546631","title":"国药现代最新公告：子公司维生素B12注射液通过一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2660546631","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660546631?lang=zh_cn&edition=full","pubTime":"2026-08-18 17:40","pubTimestamp":1787046012,"startTime":"0","endTime":"0","summary":"国药现代(600420.SH)公告称，公司全资子公司国药容生收到国家药监局核准签发的《药品补充申请批准通知书》，批准维生素B12注射液增加1ml:1mg规格并通过仿制药质量和疗效一致性评价。该药品主要用于巨幼细胞性贫血及神经系统病变辅助治疗。2025年该药品在全国公立医疗机构及城市药店销售额为6718万元。截至目前，国药容生累计研发投入约316.32万元。此次过评有利于产品市场拓展，但对公司当期经营业绩不会产生重大影响。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081800031248.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","600420","BK0010","BK0082","BK0239","BK0020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660170845","title":"股市必读：国药现代新发布《关于全资子公司药品通过仿制药一致性评价的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2660170845","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660170845?lang=zh_cn&edition=full","pubTime":"2026-08-17 01:20","pubTimestamp":1786900818,"startTime":"0","endTime":"0","summary":"公司公告汇总：全资子公司阿莫西林克拉维酸钾干混悬剂通过仿制药一致性评价，2025年该药品全国公立医疗机构及城市药店销售额为2.79亿元。公司公告汇总关于全资子公司药品通过仿制药一致性评价的公告上海现代制药股份有限公司全资子公司国药集团威奇达药业有限公司收到国家药品监督管理局核准签发的《药品补充申请批准通知书》，阿莫西林克拉维酸钾干混悬剂通过仿制药质量和疗效一致性评价。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081700000489.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","BK0082","BK0239","BK0010","600420","BK0020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659147982","title":"国药现代（600420）披露全资子公司药品通过仿制药一致性评价公告，8月14日股价上涨0.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2659147982","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659147982?lang=zh_cn&edition=full","pubTime":"2026-08-14 22:14","pubTimestamp":1786716861,"startTime":"0","endTime":"0","summary":"截至2026年8月14日收盘，国药现代报收于8.73元，较前一交易日上涨0.11%，最新总市值为117.08亿元。近日，上海现代制药股份有限公司全资子公司国药集团威奇达药业有限公司收到国家药品监督管理局核准签发的《药品补充申请批准通知书》，阿莫西林克拉维酸钾干混悬剂通过仿制药质量和疗效一致性评价。该药品主要用于治疗产酶细菌引起的感染，目前已有其他企业通过一致性评价。2025年该药品在全国公立医疗机构及城市药店销售额为2.79亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081400040029.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0010","BK0239","BK0132","BK0020","BK0082","600420"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659511797","title":"国药现代最新公告：子公司阿莫西林克拉维酸钾干混悬剂通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2659511797","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659511797?lang=zh_cn&edition=full","pubTime":"2026-08-14 17:27","pubTimestamp":1786699666,"startTime":"0","endTime":"0","summary":"国药现代(600420.SH)公告称，公司全资子公司国药威奇达收到国家药监局核准签发的《药品补充申请批准通知书》，批准阿莫西林克拉维酸钾干混悬剂通过仿制药质量和疗效一致性评价。该药品2025年全国公立医疗机构及城市药店销售额为2.79亿元。截至目前，国药威奇达用于开展该项目的累计研发投入约1623万元。本次0.15625g规格通过一致性评价将进一步促进该产品未来的市场拓展和销售，对公司当期经营业绩不会产生重大影响。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081400029182.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","BK0020","600420","BK0010","BK0082","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659158870","title":"8月13日国药现代发生1笔大宗交易 成交金额1.37亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2659158870","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659158870?lang=zh_cn&edition=full","pubTime":"2026-08-13 17:39","pubTimestamp":1786613951,"startTime":"0","endTime":"0","summary":"证券之星消息，8月13日国药现代发生大宗交易，交易数据如下：大宗交易成交价格8.67元，相对当日收盘价折价0.57%，成交1583.46万股，成交金额13728.6万元，买方营业部为国泰海通证券股份有限公司济南经十路证券营业部，卖方营业部为华龙证券股份有限公司济南经十东路证券营业部。近三个月该股共发生1笔大宗交易，合计成交15.83万手，折价成交1笔。截至2026年8月13日收盘，国药现代报收于8.72元，上涨0.81%，换手率0.93%，成交量12.42万手，成交额1.08亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081300029283.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","BK0010","600420","BK0239","BK0020","BK0082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658917973","title":"股市必读：国药现代新发布《2026年第一次临时股东会会议资料》","url":"https://stock-news.laohu8.com/highlight/detail?id=2658917973","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658917973?lang=zh_cn&edition=full","pubTime":"2026-08-12 02:12","pubTimestamp":1786471934,"startTime":"0","endTime":"0","summary":"截至2026年8月11日收盘，国药现代报收于8.72元，下跌0.34%，换手率0.64%，成交量8.56万手，成交额7513.94万元。当日关注点交易信息汇总：8月11日主力资金净流入240.24万元，占总成交额3.2%。公司公告汇总：国药现代召开2026年第一次临时股东会，审议董事及高管薪酬管理制度，并提名冯军、王永利为董事候选人。会议采取现场与网络投票相结合方式，选举采用累积投票制。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081200002097.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0020","BK0010","BK0239","600420","BK0132","BK0082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658937880","title":"国药现代（600420）披露2026年第一次临时股东会会议资料，8月10日股价上涨0.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658937880","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658937880?lang=zh_cn&edition=full","pubTime":"2026-08-10 22:39","pubTimestamp":1786372759,"startTime":"0","endTime":"0","summary":"截至2026年8月10日收盘，国药现代报收于8.75元，较前一交易日上涨0.57%，最新总市值为117.35亿元。该股当日开盘8.7元，最高8.87元，最低8.68元，成交额达9825.73万元，换手率为0.83%。近日，国药现代发布2026年第一次临时股东会会议资料。公告显示，公司拟召开2026年第一次临时股东会，审议《董事、高级管理人员薪酬管理制度》及选举董事事项。会议拟选举冯军、王永利为公司董事候选人，任期至本届董事会届满。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081000034510.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0082","BK0132","BK0239","BK0020","600420","BK0010"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658608888","title":"股市必读：国药现代新发布《关于全资子公司获得药品注册证书的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2658608888","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658608888?lang=zh_cn&edition=full","pubTime":"2026-08-10 02:05","pubTimestamp":1786298716,"startTime":"0","endTime":"0","summary":"公司公告汇总关于全资子公司获得药品注册证书的公告上海现代制药股份有限公司全资子公司国药集团容生制药有限公司收到国家药品监督管理局核准签发的比索洛尔氨氯地平片《药品注册证书》，该药品注册分类为化学药品4类，视同通过一致性评价。该产品适用于目前同时服用与复方制剂剂量相同的单药且血压控制良好的高血压患者。此次获批丰富了公司心血管领域的产品线，对公司未来发展具有积极影响，但对当期经营业绩无重大影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081000000904.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0082","BK0239","BK0132","600420","BK0010","BK0020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658567539","title":"每周股票复盘：国药现代（600420）拟中选五款集采药品","url":"https://stock-news.laohu8.com/highlight/detail?id=2658567539","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658567539?lang=zh_cn&edition=full","pubTime":"2026-08-09 02:30","pubTimestamp":1786213832,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘，国药现代报收于8.7元，较上周的8.84元下跌1.58%。本周，国药现代8月4日盘中最高价报8.99元。本周关注点公司公告汇总：盐酸戊乙奎醚注射液等五款药品拟中选第十二批全国药品集中采购。会议表决结果均为同意7票，反对0票，弃权0票。股权登记日为2026年8月12日，中小投资者对董事选举议案将单独计票。采购周期至2029年12月31日，协议每年一签或签至周期结束。拟中选结果需公示并以最终公告为准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080900000720.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","BK0020","BK0239","BK0082","BK0010","600420"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657365858","title":"国药现代（600420）披露全资子公司获得药品注册证书，8月6日股价下跌1.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657365858","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657365858?lang=zh_cn&edition=full","pubTime":"2026-08-06 22:40","pubTimestamp":1786027224,"startTime":"0","endTime":"0","summary":"截至2026年8月6日收盘，国药现代报收于8.58元，较前一交易日下跌1.27%，最新总市值为115.07亿元。该股当日开盘8.68元，最高8.69元，最低8.51元，成交额达6900.31万元，换手率为0.6%。近日，国药现代披露公告显示，其全资子公司国药集团容生制药有限公司收到国家药品监督管理局核准签发的比索洛尔氨氯地平片《药品注册证书》，该药品注册分类为化学药品4类，视同通过一致性评价。截至目前，项目累计研发投入约705.51万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080600040138.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0010","BK0082","600420","BK0132","BK0020","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657864816","title":"国药现代(600420.SH)子公司获比索洛尔氨氯地平片药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2657864816","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657864816?lang=zh_cn&edition=full","pubTime":"2026-08-06 16:46","pubTimestamp":1786005984,"startTime":"0","endTime":"0","summary":"智通财经APP讯，国药现代(600420.SH)发布公告，近日，公司全资子公司国药集团容生制药有限公司(简称国药容生)收到国家药品监督管理局核准签发的比索洛尔氨氯地平片《药品注册证书》。比索洛尔氨氯地平片作为高血压治疗的替代疗法，适用于目前同时服用与复方制剂剂量相同的单药且血压控制良好的患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1476780.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0082","MXPmain","BK0132","600420","EWW","BK0020","BK0010","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657968541","title":"国药现代：坚持“内生+外延”双轮驱动是公司明确的发展路径","url":"https://stock-news.laohu8.com/highlight/detail?id=2657968541","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657968541?lang=zh_cn&edition=full","pubTime":"2026-08-06 16:18","pubTimestamp":1786004304,"startTime":"0","endTime":"0","summary":"证券之星消息，国药现代08月06日在投资者关系平台上答复投资者关心的问题。在更换集团体系内人员背景下，公司经营未见明显改善，目前股价持续处于破净状态。公司人事调整不会影响既定的战略方向与发展目标，坚持“内生+外延”双轮驱动是公司明确的发展路径。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080600025737.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600420","BK0082","BK0132","BK0020","BK0010"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657468546","title":"国药现代：新聘总裁及董事将助力公司高质量发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2657468546","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657468546?lang=zh_cn&edition=full","pubTime":"2026-08-06 16:15","pubTimestamp":1786004110,"startTime":"0","endTime":"0","summary":"证券之星消息，国药现代08月06日在投资者关系平台上答复投资者关心的问题。公司新近聘任的总裁及提名董事均拥有深厚的行业经验和良好的教育背景，这也将助力公司持续推进中长期战略发展规划，积极采取各项措施推动公司高质量发展。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080600025387.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","BK0082","BK0239","BK0010","600420","BK0020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657458685","title":"国药现代：沙库巴曲缬沙坦钠片和布瑞哌唑片处于CDE审评审批阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2657458685","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657458685?lang=zh_cn&edition=full","pubTime":"2026-08-06 16:15","pubTimestamp":1786004110,"startTime":"0","endTime":"0","summary":"证券之星消息，国药现代08月06日在投资者关系平台上答复投资者关心的问题。贵公司的沙库巴曲缬沙坦、他克莫司胶囊、布瑞哌唑片三款仿制药大单品是什么情况？根据医药行业药物研发审批流程，整个研发期间周期长、风险高，国药致君坪山的沙库巴曲缬沙坦钠片和国药现代的布瑞哌唑片目前均已处于CDE审评审批阶段，他克莫司胶囊已通过一致性评价，相关情况可参见公司有关公告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080600025388.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0082","BK0132","600420","BK0020","BK0010","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657685113","title":"国药现代：不存在国有资产流失的情况","url":"https://stock-news.laohu8.com/highlight/detail?id=2657685113","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657685113?lang=zh_cn&edition=full","pubTime":"2026-08-06 16:12","pubTimestamp":1786003941,"startTime":"0","endTime":"0","summary":"1.二级市场股票价格受多重因素影响而波动，属于正常的市场现象，公司目前生产经营正常有序，且保持了稳定的现金分红水平，国药集团及其一致行动人长期稳定持有公司股票，不存在国有资产流失的情况。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080600025120.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600420","BK0020","BK0010","BK0132","BK0239","BK0082"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1787289403727,"stockEarnings":[{"period":"1week","weight":0.0092},{"period":"1month","weight":0.0103},{"period":"3month","weight":-0.0095},{"period":"6month","weight":-0.1538},{"period":"1year","weight":-0.2017},{"period":"ytd","weight":-0.1095}],"compareEarnings":[{"period":"1week","weight":-0.0059},{"period":"1month","weight":0.0102},{"period":"3month","weight":-0.0509},{"period":"6month","weight":-0.0437},{"period":"1year","weight":0.0365},{"period":"ytd","weight":-0.0164}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海现代制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"36225人(较上一季度增加1.00%)","perCapita":"37023股","listingDate":"2004-06-16","address":"上海市浦东新区建陆路378号","registeredCapital":"134117万元","survey":" 上海现代制药股份有限公司的主营业务是医药产品研发、生产与销售。公司的主要产品是6-APA、7-ACA、D-7ACA、青霉素工业钾盐、头孢曲松钠粗盐、氨苄西林酸。在制剂产品方面，根据米内网数据库显示，公司头孢呋辛酯片、注射用甲泼尼龙琥珀酸钠国内市场占有率稳居行业第一；头孢克肟颗粒市场份额进一步提升，展现出良好的增长态势；硝苯地平控释片、盐酸米那普仑片市场占有率稳居仿制药企业第一。","listedPrice":8.08},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"国药现代(600420)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供国药现代(600420)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"国药现代,600420,国药现代股票,国药现代股票老虎,国药现代股票老虎国际,国药现代行情,国药现代股票行情,国药现代股价,国药现代股市,国药现代股票价格,国药现代股票交易,国药现代股票购买,国药现代股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"国药现代(600420)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供国药现代(600420)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}